De Facto Communications has won the corporate PR brief from UK drug developer BTG, with the task of helping the former public sector IP consultancy reinvent itself as a leading international drug development business. De Facto will help shape the brand reputation of BTGs new business offering.
As a former IP group BTG is largely known as a generalist business with core technology in electronics, telecoms, physical sciences, medical devices and new medicines. After a radical restructuring the company has over 50 novel projects at various stages of development in its pipeline and is progressing rapidly thanks to robust in licensing activity.
With a new strategy, focused largely on developing potential new medicines for the treatment of disease in the areas of Ageing, Neuroscience and Oncology the company looks set for a successful future and is on target to maintain profitability into 2007, a notoriously difficult target in the world of early stage drugs.
BTG is headquartered in London with offices in the US and Japan. De Facto is developing a B2B PR campaign to promote the company’s repositioning, that will role out globally, ensuring BTG are on the radars of the world’s key pharmaceutical and biotechnology leaders.
- END –
For more information contact Maria Patey at De Facto on 020 7861 3838 or for more information on De Facto visit www.defacto.com
